SEC Info - Sarepta Therapeutics, Inc. - ‘8-K’ for 6/2/22

SEC Info℠

Home

My Interests

Help

Please Sign In

Database maintenance is being performed. If something doesn’t work, please try again soon.

Sarepta Therapeutics, Inc. – ‘8-K’ for 6/2/22 – ‘EX-10.1’

On: Friday, 6/3/22, at 4:20pm ET · For: 6/2/22 · Accession #: 950170-22-11164 · File #: 1-14895

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/03/22  Sarepta Therapeutics, Inc.        8-K:5,9     6/02/22   11:250K                                   Donnelley … Solutions/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     49K 
 2: EX-10.1     Material Contract                                   HTML     11K 
 6: R1          Document And Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- srpt-20220602_htm                   XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.LAB  XBRL Labels -- srpt-20220602_lab                     XML     40K 
 4: EX-101.PRE  XBRL Presentations -- srpt-20220602_pre              XML     31K 
 3: EX-101.SCH  XBRL Schema -- srpt-20220602                         XSD     11K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
11: ZIP         XBRL Zipped Folder -- 0000950170-22-011164-xbrl      Zip     13K

‘EX-10.1’ — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EX-10.1

Exhibit 10.1

AMENDMENT NO. 2

TO THE

SAREPTA THERAPEUTICS, INC.

2018 EQUITY INCENTIVE Plan

WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2018 Equity Incentive Plan (the “Plan”);

WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company (the “Board”) on April 3, 2020 and the Company’s stockholders on June 4, 2020;

WHEREAS, pursuant to Section 20 of the Plan, the “Administrator” (defined under the Plan as the Board or any of its committees) may amend the Plan from time to time subject to Company stockholder approval; and

WHEREAS, the Board, as Administrator, has determined that it is in the best interests of the Company and its stockholders to further amend the Plan to increase the number of authorized shares under the Plan by 2,500,000 shares of common stock of the Company, as authorized under the Plan.

NOW, THEREFORE, subject to the approval of the Company’s stockholders at the Company’s annual meeting on June 2, 2022, the Plan hereby is amended, effective April 5, 2022, the date of approval by the Board, as follows:

Section 3(a) of the Plan, entitled “Stock Subject to the Plan,” shall be replaced in its entirety by the following:

“(a) Stock Subject to the Plan. Subject to adjustment pursuant to Section 15(a) of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan is 10,687,596 Shares, which reflects (i) 2,500,000 new shares subject to the Second Amendment to the Plan (ii) 3,800,000 Shares subject to the First Amendment to the Plan; (iii) 2,900,000 Shares approved by stockholders on June 6, 2018; and (iv) 1,487,596 Shares, which was the maximum number of Shares available under the Amended and Restated 2011 Equity Incentive Plan (the “2011 Plan”) as of April 11, 2018, plus the number of Shares subject to outstanding awards under the 2011 Plan that expire or otherwise terminate without having been exercised in full, or are forfeited to or repurchased by us, up to a maximum of 2,412,466 Shares; provided, however, that such aggregate number of Shares available for issuance under the Plan shall be reduced by 1.41 shares for each Share delivered in settlement of any Full Value Award and, provided further, that no more than 9,200,000 Shares may be issued upon the exercise of Incentive Stock Options. The Shares may be authorized, but unissued, or reacquired Common Stock.”

Except as modified herein, the Plan is hereby specifically ratified and affirmed.

Approved by the Board on April 5, 2022.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	6/3/22	4
For Period end:	6/2/22	3, 4, DEF 14A
	4/5/22	8-K
	6/4/20	8-K, DEF 14A, PRE 14A
	4/3/20
	6/6/18	8-K, DEF 14A
	4/11/18
		List all Filings

9 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 2/28/24  Sarepta Therapeutics, Inc.        10-K       12/31/23  119:18M                                    Donnelley … Solutions/FA
 8/02/23  Sarepta Therapeutics, Inc.        S-8         8/02/23    4:69K                                    Donnelley … Solutions/FA
 2/28/23  Sarepta Therapeutics, Inc.        10-K       12/31/22  119:23M                                    Donnelley … Solutions/FA
 8/02/22  Sarepta Therapeutics, Inc.        S-8         8/02/22    4:58K                                    Donnelley … Solutions/FA
 8/02/22  Sarepta Therapeutics, Inc.        10-Q        6/30/22   79:11M                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0000950170-22-011164 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)